PROTAC递送面临的挑战与机遇。 - Suppr

Suppr

超能文献

Challenges and opportunities for PROTAC delivery.

作者信息

Benowitz Andrew B, Scott-Stevens Paul T, Harling John D

机构信息

Medicine Design, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, UK.

In Vitro/In Vivo Translation, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, UK.

出版信息

Future Med Chem. 2022 Jan;14(3):119-121. doi: 10.4155/fmc-2021-0223. Epub 2021 Sep 16.

DOI:10.4155/fmc-2021-0223

PMID:34528453

Abstract

摘要

相似文献

Challenges and opportunities for PROTAC delivery.

Future Med Chem. 2022 Jan;14(3):119-121. doi: 10.4155/fmc-2021-0223. Epub 2021 Sep 16.

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.

Eur J Med Chem. 2021 Jan 15;210:112981. doi: 10.1016/j.ejmech.2020.112981. Epub 2020 Oct 31.

New approaches for small molecule-induced protein degradation.

Future Med Chem. 2021 Mar;13(5):439-441. doi: 10.4155/fmc-2020-0343. Epub 2021 Jan 13.

Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.

J Med Chem. 2021 Jun 10;64(11):7296-7311. doi: 10.1021/acs.jmedchem.0c01313. Epub 2021 May 27.

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.

Eur J Med Chem. 2022 Jan 5;227:113967. doi: 10.1016/j.ejmech.2021.113967. Epub 2021 Nov 2.

Small-molecule PROTACs: novel agents for cancer therapy.

Future Med Chem. 2020 May;12(10):915-938. doi: 10.4155/fmc-2019-0340. Epub 2020 Apr 9.

In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application.

J Chem Inf Model. 2019 Apr 22;59(4):1634-1644. doi: 10.1021/acs.jcim.8b00872. Epub 2019 Feb 15.

Optical control of targeted protein degradation.

Cell Chem Biol. 2021 Jul 15;28(7):969-986. doi: 10.1016/j.chembiol.2021.05.010. Epub 2021 Jun 10.

Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.

ACS Chem Biol. 2018 Sep 21;13(9):2758-2770. doi: 10.1021/acschembio.8b00692. Epub 2018 Aug 30.

Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC).

Bioorg Chem. 2022 Feb;119:105508. doi: 10.1016/j.bioorg.2021.105508. Epub 2021 Nov 29.

引用本文的文献

PROTAC Technology as a New Tool for Modern Pharmacotherapy.

Molecules. 2025 May 11;30(10):2123. doi: 10.3390/molecules30102123.

PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation.

Pharmaceutics. 2025 Apr 9;17(4):501. doi: 10.3390/pharmaceutics17040501.

Targeted protein degradation for cancer therapy.

Nat Rev Cancer. 2025 Apr 25. doi: 10.1038/s41568-025-00817-8.

Targeted protein degradation: advances in drug discovery and clinical practice.

Signal Transduct Target Ther. 2024 Nov 6;9(1):308. doi: 10.1038/s41392-024-02004-x.

Cocrystallization of Gefitinib Potentiate Single-Dose Oral Administration for Lung Tumor Eradication via Unbalancing the DNA Damage/Repair.

Pharmaceutics. 2023 Nov 30;15(12):2713. doi: 10.3390/pharmaceutics15122713.

Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines.

Bioconjug Chem. 2023 Nov 15;34(11):2049-2054. doi: 10.1021/acs.bioconjchem.3c00366. Epub 2023 Nov 2.

Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs.

Pharmaceutics. 2023 Jan 3;15(1):156. doi: 10.3390/pharmaceutics15010156.

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.

Acta Pharm Sin B. 2022 Jul;12(7):2990-3005. doi: 10.1016/j.apsb.2022.02.022. Epub 2022 Feb 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Challenges and opportunities for PROTAC delivery.

Future Med Chem. 2022 Jan;14(3):119-121. doi: 10.4155/fmc-2021-0223. Epub 2021 Sep 16.

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.

Eur J Med Chem. 2021 Jan 15;210:112981. doi: 10.1016/j.ejmech.2020.112981. Epub 2020 Oct 31.

New approaches for small molecule-induced protein degradation.

Future Med Chem. 2021 Mar;13(5):439-441. doi: 10.4155/fmc-2020-0343. Epub 2021 Jan 13.

Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.

J Med Chem. 2021 Jun 10;64(11):7296-7311. doi: 10.1021/acs.jmedchem.0c01313. Epub 2021 May 27.

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.

Eur J Med Chem. 2022 Jan 5;227:113967. doi: 10.1016/j.ejmech.2021.113967. Epub 2021 Nov 2.

Small-molecule PROTACs: novel agents for cancer therapy.

Future Med Chem. 2020 May;12(10):915-938. doi: 10.4155/fmc-2019-0340. Epub 2020 Apr 9.

In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application.

J Chem Inf Model. 2019 Apr 22;59(4):1634-1644. doi: 10.1021/acs.jcim.8b00872. Epub 2019 Feb 15.

Optical control of targeted protein degradation.

Cell Chem Biol. 2021 Jul 15;28(7):969-986. doi: 10.1016/j.chembiol.2021.05.010. Epub 2021 Jun 10.

Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.

ACS Chem Biol. 2018 Sep 21;13(9):2758-2770. doi: 10.1021/acschembio.8b00692. Epub 2018 Aug 30.

Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC).

Bioorg Chem. 2022 Feb;119:105508. doi: 10.1016/j.bioorg.2021.105508. Epub 2021 Nov 29.

引用本文的文献

PROTAC Technology as a New Tool for Modern Pharmacotherapy.

Molecules. 2025 May 11;30(10):2123. doi: 10.3390/molecules30102123.

PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation.

Pharmaceutics. 2025 Apr 9;17(4):501. doi: 10.3390/pharmaceutics17040501.

Targeted protein degradation for cancer therapy.

Nat Rev Cancer. 2025 Apr 25. doi: 10.1038/s41568-025-00817-8.

Targeted protein degradation: advances in drug discovery and clinical practice.

Signal Transduct Target Ther. 2024 Nov 6;9(1):308. doi: 10.1038/s41392-024-02004-x.

Cocrystallization of Gefitinib Potentiate Single-Dose Oral Administration for Lung Tumor Eradication via Unbalancing the DNA Damage/Repair.

Pharmaceutics. 2023 Nov 30;15(12):2713. doi: 10.3390/pharmaceutics15122713.

Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines.

Bioconjug Chem. 2023 Nov 15;34(11):2049-2054. doi: 10.1021/acs.bioconjchem.3c00366. Epub 2023 Nov 2.

Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs.

Pharmaceutics. 2023 Jan 3;15(1):156. doi: 10.3390/pharmaceutics15010156.

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.

Acta Pharm Sin B. 2022 Jul;12(7):2990-3005. doi: 10.1016/j.apsb.2022.02.022. Epub 2022 Feb 26.